SCHEMBL2179376

SCHEMBL2179376

CC(c1ccccc1)N1CCC(NC(=O)OC(C)(C)C)C(O)C1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.42
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
CCR5 P51681 1/20 0.42
KDM4D Q6B0I6 4/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KCNA3 P22001 1/20 0.39
CTSK P43235 3/20 0.39
EPHX2 P34913 1/20 0.39
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
CHRM4 P08173 1/20 0.39
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179372 1.00 DRD4 (0.42) DRD4KDM1AMAOBCCR5KDM4D
SCHEMBL2179381 1.00 DRD4 (0.42) DRD4KDM1AMAOBCCR5KDM4D
SCHEMBL2179751 0.89 CCR5 (0.41) KDM1AMAOBCCR5KDM4DKMT2A
SCHEMBL2179748 0.89 CCR5 (0.41) KDM1AMAOBCCR5KDM4DKMT2A
SCHEMBL2179754 0.89 CCR5 (0.41) KDM1AMAOBCCR5KDM4DKMT2A
SCHEMBL2178311 0.89 DRD4 (0.45) DRD4CCR5CTSKCHRM4CYP2D6
SCHEMBL2178306 0.89 DRD4 (0.45) DRD4CCR5CTSKCHRM4CYP2D6
SCHEMBL2178302 0.89 DRD4 (0.45) DRD4CCR5CTSKCHRM4CYP2D6
SCHEMBL2178355 0.86 DRD4 (0.43) DRD4CTSKCHRM4CYP2D6
SCHEMBL2178353 0.86 DRD4 (0.43) DRD4CTSKCHRM4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2351738-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL Sumitomo Chemical Company, Limited (JP) 2011-08-03 EP disclosed
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-14 US disclosed
US-20110166357-A1 METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166357-A1 METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL RPS27L, OSGEP, RPLP1 DRD4 36/4885KDM1A 2921/4885MAOB 1058/4885
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL TEAD4, TEAD3, TEAD2 DRD4 79/4885KDM1A 1392/4885MAOB 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.